株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

癌免疫療法取引動向:2011〜2015年

Immuno-Oncology Deal Trends, 2011-15

発行 Datamonitor Healthcare 商品コード 363586
出版日 ページ情報 英文 58 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=111.09円で換算しております。
Back to Top
癌免疫療法取引動向:2011〜2015年 Immuno-Oncology Deal Trends, 2011-15
出版日: 2016年03月16日 ページ情報: 英文 58 Pages
概要

癌免疫療法は、癌の治療法を劇的に変える可能性を秘めた医療の新たな分野です。大手および中堅の製薬会社は、同分野に注力するための契約締結を進めています。

当レポートでは、癌免疫療法取引動向について調査し、過去5年間の癌免疫療法取引動向と成長、主要企業、最も影響力のある企業が導入する戦略などについてまとめています。

エグゼクティブサマリー

癌免疫療法:概要

  • 癌免疫療法は、産業界、学術界、および政府により複合的にイニシアティブがとられている
  • 参考文献

癌免疫療法取引動向

  • 癌免疫療法の取引額は劇的に増加
  • Bristol-Myers SquibbとMerck & Coがトップ企業であった
  • 癌免疫療法が癌分野全体の取引額のほとんどを占める
  • 特に肺癌やメラノーマなどの固形腫瘍が取引をリード
  • 非ホジキンリンパ腫と骨髄腫は全体のシェアにおいて減少
  • PD-L1/PD-1が独占
  • 癌免疫療法の標的は適応によって変わる
  • 参考文献

癌免疫療法の併用:連携動向

  • 併用が癌免疫療法取引のけん引力に
  • 併用連携が独自の特性に
  • 併用連携
  • 参考文献

癌免疫療法取引におけるケーススタディ

  • AstraZenecaは併用と血液癌においてdurvalumabに高い期待を寄せている
  • Bristol-Myers Squibbは癌免疫療法におけるリーダーシップを広げようとしている
  • Celgeneは血液癌に影響を及ぼそうとしている
  • GlaxoSmithKlineは代替的標的を模索している
  • Merck & CoはKeytrudaとの併用を当てにしている
  • Rocheのatezolizumabは膀胱癌で進化するも重要なのは併用とPD-L1の標的化
  • 参考文献

付録

目次
Product Code: DMKC0154383

Immuno-oncology is an emerging field in medicine that has the potential to radically change how cancer is treated. The Big Pharma and Mid Pharma peer sets are an integral part of development and have been furthering efforts via deal-making. The peer groups' deal volume in immuno-oncology has grown over sevenfold from 2011 to

2015. More than 50% of the immuno-oncology deals between 2011 and 2015 involved testing combinations that may eventually address previously unresponsive patients and/or additional tumor types. Combination agreements are structured differently to traditional licensing deals and are often pre-competitive in nature, early stage, and involve only one or two single studies.

This report addresses the following questions:

  • What is the growth of immuno-oncology deal-making over the last five years in volume and dollar value, and how does that compare with overall oncology deal-making?
  • Who are the top players in immuno-oncology deal-making, and what were the structures of their key deals?
  • Which solid and hematological tumor indications and anticancer immunotherapy targets are most involved immuno-oncology deals?
  • What strategies are being implemented by some of the most influential companies in immuno-oncology?

TABLE OF CONTENTS

EXECUTIVE SUMMARY

IMMUNO-ONCOLOGY: A BRIEF INTRODUCTION

  • 1. Immuno-oncology has sparked multiple industry, academic, and government initiatives
  • 2. Bibliography

KEY TRENDS IN IMMUNO-ONCOLOGY DEAL-MAKING

  • 3. Immuno-oncology deal volume has rapidly increased
  • 4. Bristol-Myers Squibb and Merck & Co were the top immuno-oncology dealmakers
  • 5. Immuno-oncology represented most of the overall oncology deal value
  • 6. Solid tumors, especially lung cancer and melanoma, led immuno-oncology deals
  • 7. Non-Hodgkin's lymphoma and myeloma decreasing in overall share of deals
  • 8. PD-L1/PD-1 dominated immuno-oncology deals
  • 9. Immuno-oncology targets vary across indications
  • 10. Bibliography

IMMUNO-ONCOLOGY COMBINATIONS: COLLABORATIVE EFFORTS

  • 11. Combinations are the driving force in immuno-oncology deal-making
  • 12. Combination collaborations have unique characteristics
  • 13. Combination collaborations
  • 14. Bibliography

IMMUNO-ONCOLOGY DEAL-MAKING CASE STUDIES

  • 15. AstraZeneca has high hopes for durvalumab in combinations and in hematological cancers
  • 16. Bristol-Myers Squibb aims to extend immuno-oncology leadership
  • 17. Celgene is trying to make an impact in hematological cancers
  • 18. GlaxoSmithKline looks to alternative immuno-oncology targets
  • 19. Merck & Co is banking on Keytruda combinations
  • 20. Roche's atezolizumab advances in bladder cancer, but combinations and non-PD-L1 targets are of importance
  • 21. Bibliography

APPENDIX

  • 22. Scope
  • 23. Methodology
Back to Top